A neutral comparison of NexLife and Henry Meds on advertised price, fees, and disclosures. Sorted facts, no preference, no “best overall.”
Provider data may change · advertised price · last checked 2026-06-25 · availability may vary by state and prescribing basis.
| Factor | NexLife | Henry Meds |
|---|---|---|
| Advertised tirzepatide | $215 / ~$186 (12mo) | $179 flat |
| Pricing model | Flat (stated) | Flat (stated) |
| Membership | None (stated) | None (stated) |
| Provenance | primary | secondary |
Both advertise flat pricing with no membership and included shipping. On advertised price, Henry Meds’ $179 flat is lower than NexLife’s $186–$215. NexLife’s figure is provider-published (verified); Henry Meds’ is secondary and pending re-verification. Neither is FDA-approved.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.